Search

everythinglearnresearchcommunity

for

Search:↓

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

Misinformation about alopecia is common online and can harm patient choices.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Minoxidil shows promise for alopecia areata, but more research is needed before it can be recommended as a primary treatment.

Regenerative medicine is effective and safe for treating vitiligo.

Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Laser therapy might help regrow hair in alopecia totalis better than steroids alone.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.

Araliadiol may promote hair growth like minoxidil without being toxic.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

OXTR agonists may promote hair growth and be effective for treating hair loss.

Oral tofacitinib successfully treated total body hair loss in one patient.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

The model and estimator can predict drug exposure in kidney transplant patients well.

Tofacitinib may help treat severe hair loss, but more research is needed.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.